Back to mobile site

OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Amid Headwinds, Revenue Decline

October 27, 2026 5:19 AM EDT Send to a Friend
Citizens analyst Constantine Davides reiterated a Market Outperform rating and $11.00 price target on OptimizeRX (NASDAQ: OPRX).The analyst commented, "Can ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login